Meeting
2018 ASCO Annual Meeting
53BP1 as a predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Authors
Rachel M Hurley
Mayo Medical School, Rochester, MN
Rachel M Hurley , Andrea Elisabeth Wahner Hendrickson , Daniel W. Visscher , Peter J Ansell , Maria I Harrell , Jill M Wagner , Vivian Negron , Krista M. Goergen , Matthew John Maurer , Ann L. Oberg , Maja J. De Jonge , Carla M.L.- Van Herpen , Jourik A. Gietema , Rutger H.T. Koornstra , Agnes Jager , Martha W. den Hollander , Matthew W. Dudley , Stacie Peacock Shepherd , Elizabeth M. Swisher , Scott H. Kaufmann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 5538)
DOI
10.1200/JCO.2018.36.15_suppl.5538
Abstract #
5538
Poster Bd #
265
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Real life use of biomarkers of homologous recombination deficiency (HRD) status beyond BRCA to predict the effectiveness of PARP inhibitors in ovarian cancer patients.
First Author: Lorena Incorvaia
First Author: Emmanouil S. Saloustros
Poster
2023 ASCO Annual Meeting
Systematic high-throughput combination drug screen to enhance poly (ADP-ribose) polymerase (PARP) inhibitor efficacy in ovarian cancer.
First Author: Katherine Foster
Poster
2023 ASCO Annual Meeting
HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).
First Author: June Evelyn Jeon